Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 94,170,616
  • Shares Outstanding, K 1,305,930
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.21
  • Price/Sales 3.11
  • Price/Cash Flow 5.74
  • Price/Book 4.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.77 +0.47%
on 07/19/17
76.49 -5.73%
on 07/31/17
+0.42 (+0.59%)
since 07/18/17
3-Month
63.76 +13.10%
on 06/16/17
76.49 -5.73%
on 07/31/17
+7.68 (+11.92%)
since 05/18/17
52-Week
63.76 +13.10%
on 06/16/17
82.10 -12.17%
on 08/24/16
-8.48 (-10.52%)
since 08/18/16

Most Recent Stories

More News
Mylan Finalizes Settlement Agreement with DOJ for $465M

Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.

MYL : 30.72 (+0.52%)
GILD : 72.11 (-0.32%)
RHHBY : 31.2300 (-0.98%)
GSK : 38.75 (-0.77%)
AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada

AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.

ENTA : 37.96 (-3.92%)
MRK : 61.49 (-0.57%)
ABBV : 69.96 (+0.16%)
GILD : 72.11 (-0.32%)
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

MRK : 61.49 (-0.57%)
ABBV : 69.96 (+0.16%)
GILD : 72.11 (-0.32%)
BMY : 56.42 (-0.62%)
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning

Pfizer, Inc.'s (PFE) leukemia candidate, Besponsa received FDA approval, though with a boxed warning on the label.

GILD : 72.11 (-0.32%)
REGN : 467.98 (+0.85%)
PFE : 32.67 (-0.85%)
SNY : 48.19 (+0.23%)
Gilead Sciences (GILD) Approaches New Downside Target of $72.76

Shares of Gilead Sciences (NASDAQ:GILD) have bearishly opened below the pivot of $73.41 today and have reached the first support level of $73.06. Investors may be interested in a cross of the next downside...

GILD : 72.11 (-0.32%)
Gilead Receives Approval in Canada for VOSEVI(TM) (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection

- VOSEVI is the First Once-Daily, Single Tablet HCV Regimen for Re-Treatment, andCompletes Gilead's Portfolio of Sofosbuvir-Based HCV Direct-Acting Antiviral Treatments -

GILD : 72.11 (-0.32%)
Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial

Regeneron Pharmaceuticals, Inc. (REGN) announced disappointing results from a phase III study, NURSERY Pre-term on suptavumab .

BAYRY : 126.8200 (+0.55%)
GILD : 72.11 (-0.32%)
REGN : 467.98 (+0.85%)
SNY : 48.19 (+0.23%)
Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

MYL : 30.72 (+0.52%)
GILD : 72.11 (-0.32%)
Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial Progress

PALM BEACH, Florida, August 16, 2017 /PRNewswire/ --

ENDP : 8.72 (+1.04%)
GILD : 72.11 (-0.32%)
TEVA : 17.30 (+1.17%)
MBOT : 1.07 (-3.60%)
MBRX : 2.39 (-6.64%)
Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review

This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.

CELG : 127.65 (+0.05%)
VRTX : 148.13 (-0.28%)
OPHT : 2.80 (+1.82%)
IONS : 46.98 (-0.36%)
GILD : 72.11 (-0.32%)
REGN : 467.98 (+0.85%)
GLPG : 86.43 (-1.12%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 72.99
1st Resistance Point 72.55
Last Price 72.11
1st Support Level 71.75
2nd Support Level 71.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.